Finnegan client AbbVie secures non-institution decisions for Humira® patents

A biosimilar drug manufacturer filed inter partes review (IPR) petitions challenging two patents held by Finnegan client AbbVie Biotechnology Ltd, which cover methods of treating Crohn’s disease and ulcerative colitis using Humira®. The Patent Trial and Appeal Board (PTAB) issued two decisions, each denying institution on all grounds and holding that the petitioner failed to establish a reasonable likelihood that any of the challenged claims were unpatentable.